Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2024-11-22 Capital/Financing Update
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
PROSPECTUS
Capital/Financing Update Classification · 100% confidence The document is a prospectus related to the offer and sale of up to 10,000,000 ordinary shares by a selling shareholder. It includes detailed information about the share offering, the selling shareholder, the plan of distribution, risk factors, and other related disclosures. The document is a registration statement filed with the SEC, specifically a Form 424B3 prospectus, which is used for securities offerings. This type of document is not a financial report, earnings release, or management discussion, but rather a capital markets document related to financing activities. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary, confirming it is a full prospectus related to capital raising.
2024-11-22 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from NeuroSense Therapeutics Ltd. to the SEC requesting acceleration of the effectiveness of a Registration Statement No. 333-283338 on Form F-1. It is a formal communication related to the registration process for securities under the Securities Act of 1933. The document is short (1219 characters) and does not contain financial statements or detailed financial data. It is a regulatory communication about the timing of a filing becoming effective, not the filing itself or a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-11-21 English
Regulatory Filings 2024
Regulatory Filings
2024-11-21 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a preliminary prospectus for the sale of ordinary shares by a selling shareholder. The text references the registration process, the offering details, and disclaimers typical of a registration statement. This is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities registration and offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS.
2024-11-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It discusses Nasdaq listing compliance issues, notices received, and forward-looking statements. The document does not contain financial statements or detailed financial analysis but rather regulatory updates and notices related to listing compliance. It is not an annual or quarterly report, earnings release, or audit report. It is a regulatory filing providing updates on compliance status and related disclosures. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6262 characters) and content confirm it is not merely an announcement but a substantive regulatory filing, yet it does not fit other specific categories better.
2024-11-12 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content describes a Standby Equity Purchase Agreement with Yorkville, detailing terms of potential equity sales, conditions, and related disclosures. There are no financial statements or detailed financial performance data included, only an announcement of a financing agreement. The document is about a capital raising arrangement and financing update rather than a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (7485 characters) supports it being a substantive filing rather than a brief announcement or certification.
2024-10-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.